CompletedNCT00484471
Aripiprazole added to valproate to prevent relapse in bipolarity
About this title
ABLE: Abilify in Bipolar Disorder for Long-term Effectiveness
Read the official source —Medication studyAges 18–65Multiple countries
Understand this study
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Tuenmen and 12 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateOctober 2007
- Recruitment status
- Completed
- Enrollment listed in the registry
- 127
- Sponsor
- Korea Otsuka International Asia Arab
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- China, Philippines, Taiwan, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00484471
- Official title
Show the full official title
A Double Blind, Randomized, Placebo Controlled Trial of Aripiprazole Plus Valproate in the Short-Term and Long-Term Treatment of Bipolar Disorder
Get this study by email
Recruitment & locations
CompletedTuenmen, Hong Kong · Mandaluyong, Philippines · Manila, Philippines
8 more locations
- Quezon, Philippines
- Changhua, Taiwan
- Nantou City, Taiwan
- Tainan, Taiwan
- Taipei, Taiwan
- Taoyuan, Taiwan
- Bangkok, Thailand
- China
Questions about this study
Who is behind this study?
The study sponsor is Korea Otsuka International Asia Arab.
Did this study involve medication?
Yes. The study involved medication, including aripiprazole, valproate and placebo.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
